BRD7 Antibody (H-2): sc-376179
- BRD7 Antibody (H-2) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 397-473 mapping within an internal region of BRD7 of human origin
- recommended for detection of BRD7 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for BRD7 Antibody (H-2) for WB applications. This reagent is now offered in a bundle with BRD7 Antibody (H-2) (see ordering information below).
BRD7 Antibody (H-2) is a mouse monoclonal IgG1 antibody that detects BRD7 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). BRD7, also known as bromodomain containing protein 7, BP75, NAG4, or CELTIX1, is a 651 amino acid transcription regulation factor that plays a crucial role in cell cycle progression and gene expression regulation. Localized primarily in the nucleus, BRD7 is essential for maintaining proper cellular functions, as BRD7 acts as a tumor suppressor by negatively regulating the expression of key cell cycle proteins, including cyclin D1 and E2F-3, thereby inhibiting the transition from the G1 phase to the S phase of the cell cycle. This regulatory function is particularly important in the context of cancer, as overexpression of BRD7 has been shown to suppress the growth of nasopharyngeal carcinoma cells. Additionally, BRD7 interacts with the centrosome-associated protein BLOS2, which modulates BRD7′s transcriptional suppression activity on various target genes, highlighting the complexity of BRD7′s role in cellular signaling pathways. With diverse applications and significant biological implications, anti-BRD7 antibody (H-2) is an invaluable tool for researchers studying cell cycle regulation and tumor biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
BRD7 Antibody (H-2) References:
- BRD7: a novel tumor suppressor gene in different cancers. | Yu, X., et al. 2016. Am J Transl Res. 8: 742-8. PMID: 27158366
- Development of chemical probes for the bromodomains of BRD7 and BRD9. | Clark, PG., et al. 2016. Drug Discov Today Technol. 19: 73-80. PMID: 27769361
- BRD7 regulates the insulin-signaling pathway by increasing phosphorylation of GSK3β. | Golick, L., et al. 2018. Cell Mol Life Sci. 75: 1857-1869. PMID: 29127434
- BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition. | Niu, W., et al. 2020. J Exp Clin Cancer Res. 39: 30. PMID: 32028981
- The BRD7-P53-SLC25A28 axis regulates ferroptosis in hepatic stellate cells. | Zhang, Z., et al. 2020. Redox Biol. 36: 101619. PMID: 32863216
- BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma. | Chen, CL., et al. 2021. J Cancer. 12: 1507-1519. PMID: 33531996
- BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer. | Zhao, R., et al. 2021. Front Cell Dev Biol. 9: 659392. PMID: 34109174
- BRD7 improves glucose homeostasis independent of IRS proteins. | Kim, Y., et al. 2023. J Endocrinol. 258: PMID: 37578842
- BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1. | Li, L., et al. 2023. Cell Death Discov. 9: 313. PMID: 37626049
- BRD7 facilitates ferroptosis via modulating clusterin promoter hypermethylation and suppressing AMPK signaling in diabetes-induced testicular damage. | Xiao, Y., et al. 2024. Mol Med. 30: 100. PMID: 38992588
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BRD7 Antibody (H-2) | sc-376179 | 200 µg/ml | $322.00 | |||
BRD7 Antibody (H-2): m-IgG Fc BP-HRP Bundle | sc-540525 | 200 µg Ab; 10 µg BP | $361.00 |